These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25915904)

  • 41. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
    Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
    BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Steinberg BA; Kim S; Piccini JP; Fonarow GC; Lopes RD; Thomas L; Ezekowitz MD; Ansell J; Kowey P; Singer DE; Gersh B; Mahaffey KW; Hylek E; Go AS; Chang P; Peterson ED;
    Circulation; 2013 Aug; 128(7):721-8. PubMed ID: 23861512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
    Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
    Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological therapy following acute coronary syndromes in patients with atrial fibrillation: how do we balance ischaemic risk with bleeding risk?
    Fake AL; Harding SA; Matsis PP; Larsen PD
    N Z Med J; 2016 May; 129(1435):39-49. PubMed ID: 27355167
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
    Lane DA; Raichand S; Moore D; Connock M; Fry-Smith A; Fitzmaurice DA;
    Health Technol Assess; 2013 Jul; 17(30):1-188. PubMed ID: 23880057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study.
    Park J; Choi EK; Han KD; Choi YJ; Lee E; Choe W; Lee SR; Cha MJ; Lim WH; Kang J; Park KW; Oh S; Lip GYH
    PLoS One; 2019; 14(1):e0209593. PubMed ID: 30645601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study.
    Hu C; Zhang X; Liu Y; Gao Y; Zhao X; Zhou H; Luo Y; Liu Y; Wang X
    BMC Cardiovasc Disord; 2018 Jun; 18(1):120. PubMed ID: 29914380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
    Lam DH; Bell SM; Hira RS
    Curr Atheroscler Rep; 2018 Jan; 20(1):4. PubMed ID: 29349596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry.
    Gullón A; Suárez C; Díez-Manglano J; Formiga F; Cepeda JM; Pose A; Camafort M; Castiella J; Rovira E; Mostaza JM;
    Med Clin (Barc); 2017 Mar; 148(5):204-210. PubMed ID: 27993408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of Adding Antiplatelets to Oral Anticoagulants in Patients with Acute Ischemic Stroke with Atrial Fibrillation and Concomitant Large Artery Steno-Occlusion.
    Kim JT; Lee JS; Kim BJ; Park JM; Kang K; Lee SJ; Kim JG; Cha JK; Kim DH; Park TH; Park SS; Lee KB; Lee J; Hong KS; Cho YJ; Park HK; Lee BC; Yu KH; Oh MS; Kim DE; Ryu WS; Choi JC; Kwon JH; Kim WJ; Shin DI; Sohn SI; Hong JH; Park MS; Choi KH; Cho KH; Lee J; Gorelick PB; Bae HJ
    Transl Stroke Res; 2020 Dec; 11(6):1322-1331. PubMed ID: 32472251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Pareek M; Bhatt DL; Ten Berg JM; Kristensen SD; Grove EL
    Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study].
    Zhu LY; Li Q; Yu LY; Liu Y; Chen YN; Wang Z; Zhang SY; Li J; Liu Y; Zhao YL; Xi Y; Pi L; Sun YH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jul; 51(7):731-741. PubMed ID: 37460427
    [No Abstract]   [Full Text] [Related]  

  • 56. Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).
    Verheugt FWA; Ten Berg JM; Storey RF; Cuisset T; Granger CB
    J Am Coll Cardiol; 2019 Aug; 74(5):699-711. PubMed ID: 31277840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry".
    Fischer Q; Georges JL; Le Feuvre C; Sharma A; Hammoudi N; Berman E; Cohen S; Jolivet I; Silvain J; Helft G
    Int J Cardiol; 2018 Aug; 264():64-69. PubMed ID: 29776575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
    Maegdefessel L; Schlitt A; Faerber J; Bond SP; Messow CM; Buerke M; Raaz U; Werdan K; Muenzel T; Weiss C
    Med Klin (Munich); 2008 Sep; 103(9):628-32. PubMed ID: 18813885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry.
    Sherwood MW; Piccini JP; Holmes DN; Pieper KS; Steinberg BA; Fonarow GC; Allen LA; Naccarelli GV; Kowey PR; Gersh BJ; Mahaffey KW; Singer DE; Ansell JE; Freeman JV; Chan PS; Reiffel JA; Blanco R; Peterson ED; Rao SV
    Circ Cardiovasc Interv; 2020 May; 13(5):e008274. PubMed ID: 32408815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.